Supplements for Sleep Apnea: What Evidence Shows

Obstructive sleep apnea (OSA) is repeated collapse or narrowing of the upper airway during sleep, diagnosed by a sleep study showing an apnea-hypopnea index (AHI) of 5 or more events per hour with symptoms, or 15 or more regardless of symptoms. Continuous positive airway pressure (CPAP) and oral appliances (mandibular advancement devices) are the established mechanical treatments. Dietary supplements are not a category of OSA treatment recognized by sleep medicine guideline bodies; they are, at most, adjuncts aimed at the downstream inflammatory and metabolic consequences of the disease.

No dietary supplement lowers the AHI enough to substitute for CPAP or an oral appliance. A handful of small randomized trials suggest that vitamin D, N-acetylcysteine (NAC), omega-3 fatty acids, and combined vitamin C and E may reduce inflammatory or oxidative stress markers in people with OSA, but these trials are small, mostly unreplicated, and were not designed to show whether the marker changes translate into fewer apneas, better daytime function, or lower cardiovascular risk. The only non-device intervention with trial support for a clinically meaningful AHI reduction is weight loss, whether through behavioral programs, incretin-based pharmacotherapy, or bariatric surgery. Anyone considering a supplement for OSA should treat it as a possible complement to CPAP adherence and weight management, not a replacement.

Why supplements are not a substitute for CPAP or an oral appliance

CPAP, when used consistently, brings the AHI down to normal or near-normal range for most patients and is the therapy with the strongest evidence for reducing OSA-related symptoms and cardiovascular risk. Sleep medicine guideline bodies do not include dietary supplements among recommended OSA treatments. That does not mean supplements are irrelevant; it means their plausible role is narrower than "treatment" and closer to "adjunct."

What supplements are actually being tested for

OSA causes repeated cycles of hypoxia and reoxygenation during sleep, which is thought to generate oxidative stress and low-grade systemic inflammation. Several supplement trials in OSA are built on this mechanism: they measure markers such as C-reactive protein (CRP), malondialdehyde, or endothelial function rather than the AHI itself. A supplement that improves an inflammatory marker in a small trial has not been shown to improve breathing during sleep, reduce daytime sleepiness, or lower cardiovascular events. Those are separate questions, and most of the supplement literature in OSA has only answered the first one.

Vitamin D

Observational studies have repeatedly found lower serum 25-hydroxyvitamin D levels in people with OSA compared with controls, and some report an inverse relationship between vitamin D level and OSA severity. The exact prevalence figures and dose-response strength vary across studies and should be confirmed against a specific systematic review before being cited as a fixed number.

Small randomized trials of vitamin D supplementation in OSA populations have reported reductions in inflammatory markers such as CRP and IL-6, and at least one small trial reported improved subjective daytime sleepiness scores. None of the trials identified for this article showed a statistically significant reduction in AHI with vitamin D supplementation alone.

Practical framing: checking serum 25(OH)D and correcting a documented deficiency is reasonable general medical care in a patient with OSA and low vitamin D, following standard endocrinology dosing practice for deficiency correction. It should be framed to the patient as addressing a deficiency, not as an OSA treatment.

N-acetylcysteine (NAC)

NAC is a glutathione precursor with antioxidant activity. A small randomized crossover trial in patients with moderate OSA not using CPAP reported a meaningful reduction in AHI with NAC 600 mg twice daily over about a month, along with improvement in the oxygen desaturation index. This is the closest any supplement in this review comes to a direct AHI effect rather than a marker effect.

The trial was small, has not been replicated at scale, and used a crossover design whose washout period may not fully separate the treatment effects. A single small trial, however encouraging, is not sufficient to establish NAC as an OSA treatment. It is reasonable to describe this as a preliminary signal worth follow-up research, not as established efficacy. Anyone considering NAC for OSA outside of CPAP should discuss it with a sleep physician rather than substitute it for airway therapy, and the specific trial's numbers should be checked against the primary publication before being used in patient counseling.

Omega-3 fatty acids

EPA and DHA have known anti-inflammatory activity through several pathways, including reduced production of inflammatory cytokines. Small trials in OSA populations have reported reductions in markers like TNF-alpha and CRP with omega-3 supplementation in the range of roughly 2 to 3 grams per day of combined EPA and DHA, generally without a corresponding change in AHI or sleepiness scores. This dose range is broadly consistent with general cardiovascular guidance for people with elevated triglycerides, independent of the OSA-specific question.

What this does and does not support: omega-3 supplementation may be a reasonable adjunct for a patient with OSA and elevated inflammatory markers who is already adherent to CPAP, framed around cardiometabolic risk reduction rather than airway improvement. GI side effects (fishy aftertaste, loose stools) are the main tolerability issue at these doses.

Vitamin C and vitamin E together

A small crossover trial testing combined vitamin C and vitamin E in OSA patients reported normalization of endothelial function (vascular response to acetylcholine) after about six weeks, with effects comparable in size to what CPAP produces on the same measure over a similar period. This is a vascular surrogate marker, not an airway or sleepiness outcome, and it comes from one small trial that should be checked against the primary source before being treated as settled.

No trial identified here has tested whether antioxidant vitamin combinations reduce hard cardiovascular outcomes (heart attack, stroke, death) specifically in OSA patients. Given the low cost and generally low risk of vitamin C and E at studied doses, combination use may be reasonable for a patient with documented oxidative stress markers who remains CPAP-adherent, but this is a judgment call, not a guideline recommendation.

Magnesium

Magnesium supports neuromuscular signaling, including at the neuromuscular junctions of upper airway dilator muscles, and contributes to normal sleep architecture. This is a plausible mechanism for a role in OSA, since upper airway collapse involves impaired tone in muscles like the genioglossus. Magnesium deficiency is also common in metabolic syndrome, which overlaps heavily with OSA.

No dedicated randomized controlled trial testing magnesium supplementation specifically in an OSA population was identified for this article. Trials of magnesium for general sleep quality in mixed, non-OSA populations exist and report modest subjective improvement, but extrapolating that to OSA is a reasonable hypothesis, not established evidence. Checking serum or RBC magnesium is reasonable in an OSA patient with risk factors for deficiency (loop diuretics, proton pump inhibitors, poorly controlled diabetes), and correcting a documented deficiency may help general sleep quality. It should not be presented to a patient as an OSA treatment.

Melatonin

Melatonin does not lower the AHI, and it is not treated as an OSA therapy in the sleep medicine literature. Its plausible role is narrower: helping a patient fall asleep faster and stay asleep longer while wearing CPAP, which can indirectly support CPAP adherence in people whose sleep-onset difficulty undermines mask tolerance. A 2025 expert consensus statement on the diagnosis and treatment of excessive daytime sleepiness in OSA addresses adjunctive and pharmacologic approaches to residual sleepiness in this population; it does not position dietary supplements, including melatonin, as a core treatment for OSA-related sleepiness, and its specific recommendations should be checked against the full text before being cited in patient materials (PubMed, 2025).

If poor sleep onset is the barrier to consistent CPAP use, melatonin is a reasonable topic to raise with a sleep physician as a sleep-aid strategy, framed around adherence rather than apnea reduction.

Weight loss: the intervention with the clearest AHI effect

Among non-device approaches, weight loss has the most consistent trial support for reducing AHI, with larger mean weight loss generally producing larger AHI reductions in obese patients with OSA. Bariatric surgery and structured behavioral weight-loss programs both have supporting trial data for this relationship.

Incretin-based pharmacotherapy (GLP-1/GIP receptor agonists) has more recently been studied specifically in OSA populations with obesity, and at least one agent has received an FDA-approved indication for moderate-to-severe OSA in adults with obesity based on phase 3 trial results showing a substantial AHI reduction with weight loss (reported in 2024). The exact approval date, trial population, and effect sizes should be verified against the current FDA label and the published trial report before being used in patient-facing material, since drug labeling and indications can change and the numbers reported in secondary sources are not reliable enough to repeat without checking. This class of medication requires medical evaluation, has its own contraindications and side effect profile, and is a prescription decision separate from supplement use.

Supplements that target inflammation or oxidative stress operate at a different order of magnitude than weight loss or airway therapy for AHI reduction. They may be reasonable complements to a weight-management and CPAP-adherence plan; they are not alternatives to it.

Myoinositol, CoQ10, and other early-stage candidates

Myoinositol has insulin-sensitizing effects studied mainly in polycystic ovary syndrome and is of theoretical interest for the metabolic overlap with OSA, but no dedicated OSA trial was identified for this article. A small pilot study reported reduced oxidative stress markers with coenzyme Q10 in OSA patients over about a month. Both should be described as hypothesis-generating only. Neither has sufficient evidence to recommend for OSA management, and specific trial numbers circulating for either compound should be checked against a primary source before being repeated.

What is established, what is plausible, and what is not established

Established: CPAP and oral appliances reduce AHI and are the guideline-recommended OSA treatments. Weight loss reduces AHI in obese patients with OSA, with the magnitude scaling to the amount of weight lost. Melatonin does not reduce AHI.

Plausible but not established as an OSA treatment: vitamin D, NAC, omega-3 fatty acids, and combined vitamin C and E may improve inflammatory or vascular markers in OSA populations in small trials; whether this changes AHI, symptoms, or hard cardiovascular outcomes is not established. Magnesium's role in OSA specifically is a mechanistic hypothesis without a dedicated trial.

Not established: that any supplement reviewed here is an effective standalone treatment for OSA, that myoinositol or CoQ10 have a defined role in OSA, or that any supplement reduces cardiovascular events in OSA patients specifically.

Supplement-by-supplement evidence status and verification checklist

When to seek care rather than try a supplement

New or worsening loud snoring with witnessed pauses in breathing, gasping awakenings, unrefractory daytime sleepiness, or difficulty concentrating that affects driving or work safety warrants evaluation by a physician, ideally with a sleep study, rather than self-treatment with supplements. Chest pain, new arrhythmia symptoms, or severe unexplained shortness of breath require urgent evaluation, not a delayed supplement trial.